Morphological diagnosis of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central review. /// K.Kuriyama, M.Tomonaga, T.Kobayashi, J.Takeuchi, T.Ohshima, S.Furusawa, K.Saitoh, R.Ohno for the Japan Adult Leukemia Study Group. /// Inter J Hematol 73(1):93-99,2001
Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis. /// Ohnishi K, Ino T, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Kusumoto S, Kuriyama K, Hotta T, Ohno R. /// Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S59-64.
Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). /// Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake H, Ohno R. /// Cancer Chemother Pharmacol 48 Suppl 1:S65-71,2001
Clinicopathologic characteristics of leukemia in Japanese children and young adults. /// Horibe K, Tsukimoto I, Ohno R. /// Leukemia 15(8):1256-1261,2001
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. /// Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, and Naoe T. /// Blood 97: 2434-2439,2001
2001年～2010年の論文
【論文タイトル /// 全著者名 /// 掲載誌】
Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. /// Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R. /// Leukemia 16(7):1259-1266,2002
Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. /// Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang YH, Motoji T, Ohno R, Nakamura Y. /// Mol Cancer Ther. 1(12): 1035-1042,2002
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. /// Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. /// Br J Haematol. 117(4): 882-885,2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. /// Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R. /// Leukemia. 16(4): 617-622,2002
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. /// Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H, Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno R. /// Jpn J Cancer Res. 93(8): 849-856,2002
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features. /// Multani PS, Tobinai K, Kakizoe T, Armitage JO, Ohno R, Sugimura T. /// Jpn J Clin Oncol. 32(9): 371-385,2002
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. /// Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C, Saito K, Akiyama H, Motoji T, Nishimura M, Shinagawa K, Ueda R, Saito H, Ohno R. /// Leukemia. 16(2): 203-208,2002
Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. /// Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F; Gran AML Study Group. /// Br J Haematol. 116(1): 103-112,2002
Rapid screening of leukemia fusion transcripts in acute leukemia by Real-time PCR. /// Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K, Kato K, Matsuyama M, Naito K, Tamimoto M, Hirai H, Saito H, Ohno R, Naoe T. /// Leuk Lymphoma 43: 2291-2299,2002
Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. /// Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang YH, Motoji T, Ohno R, Nakamura Y. /// Mol Cancer Ther. 1(12): 1035-1042,2002
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. /// Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. /// Br J Haematol. 117(4): 882-885,2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. /// Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R. /// Leukemia. 16(4): 617-622,2002
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. /// Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H, Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno R. /// Jpn J Cancer Res. 93(8): 849-856,2002
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features. /// Multani PS, Tobinai K, Kakizoe T, Armitage JO, Ohno R, Sugimura T. /// Jpn J Clin Oncol. 32(9): 371-385,2002
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. /// Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C, Saito K, Akiyama H, Motoji T, Nishimura M, Shinagawa K, Ueda R, Saito H, Ohno R. /// Leukemia. 16(2): 203-208,2002
Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. /// Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F; Gran AML Study Group. /// Br J Haematol. 116(1): 103-112,2002
Rapid screening of leukemia fusion transcripts in acute leukemia by Real-time PCR. /// Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K, Kato K, Matsuyama M, Naito K, Tamimoto M, Hirai H, Saito H, Ohno R, Naoe T. /// Leuk Lymphoma 43: 2291-2299,2002
Cytogenetic heterogeneity of acute myeloid leukaemia(AML)with trilineage dysplasia:Japan Adult Leukaemia Study Group-AML 92 study. /// Y.Miyazaki, K.Kuriyama, S.Miyawaki, S.Ohtake, H.Sakamaki, T.Matsuo, N.Emi, T.Kobayashi, T.Matsushima, K.Shinagawa, R.Ohno and M.Tomonaga for the Japan Adult Leukemia Study Group. /// Br J Haematology 120:56-62,2003
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. /// N Matsuno, M Osato, N Yamashita, M Yanagida, T Nanri, T Fukushima, T Motoji, S Kusumoto, M Towartari, R Suzuki, T Naoe, K Nishii, K Shigesada, R Ohno, H Mitsuya, Y Ito and N Asou. /// Leukemia 17:2492-2499,2003
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. /// Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T, Akao Y, Ohno R, Ohnishi K. /// Leukemia. 17(1): 1-8,2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. /// Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML Prognostic Factors Project Group. /// Semin Hematol. 40(1): 4-12. Review,2003
The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. /// Matsuo T, Kuriyama K, Miyazaki Y, Yoshida S, Tomonaga M, Emi N, Kobayashi T, Miyawaki S, Matsushima T, Shinagawa K, Honda S, Ohno R; Japan Adult Leukemia Study Group. /// Leukemia. 17(8):1538-1543,2003
Prediction of response to imatinib by cDNA microarray analysis. /// R Ohno, Y Nakamura. /// Seminars in Hematology.40(2):42-49,2003
Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. /// Ohno R, Asou N, Ohnishi K. /// Leukemia 17(8):1454-1463,2003
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. /// N Matsuno, M Osato, N Yamashita, M Yanagida, T Nanri, T Fukushima, T Motoji, S Kusumoto, M Towartari, R Suzuki, T Naoe, K Nishii, K Shigesada, R Ohno, H Mitsuya, Y Ito and N Asou. /// Leukemia 17:2492-2499,2003
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. /// Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T, Akao Y, Ohno R, Ohnishi K. /// Leukemia. 17(1): 1-8,2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. /// Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML Prognostic Factors Project Group. /// Semin Hematol. 40(1): 4-12. Review,2003
The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. /// Matsuo T, Kuriyama K, Miyazaki Y, Yoshida S, Tomonaga M, Emi N, Kobayashi T, Miyawaki S, Matsushima T, Shinagawa K, Honda S, Ohno R; Japan Adult Leukemia Study Group. /// Leukemia. 17(8):1538-1543,2003
Prediction of response to imatinib by cDNA microarray analysis. /// R Ohno, Y Nakamura. /// Seminars in Hematology.40(2):42-49,2003
Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. /// Ohno R, Asou N, Ohnishi K. /// Leukemia 17(8):1454-1463,2003
Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia. /// Ohnishi K, Ino A, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga M, Hotta T, Ohno R; Japan Adult Leukemia Study Group. /// Int J Hematol. 79(4):345-353,2004
The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL). /// Ohno R, Asou N; Japan Adult Leukemia Study Group. /// Ann Hematol. 83 Suppl 1:S77-78,2004
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. /// Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R. /// Blood.;104(12):3507-3512,2004
Biological and clinical significance of the FLT3 transcript level in acute myeloid leukemia. /// Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Ohno R, Emi N, Naoe T. /// Blood. 103:1901-1908,2004
The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL). /// Ohno R, Asou N; Japan Adult Leukemia Study Group. /// Ann Hematol. 83 Suppl 1:S77-78,2004
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. /// Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R. /// Blood.;104(12):3507-3512,2004
Biological and clinical significance of the FLT3 transcript level in acute myeloid leukemia. /// Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Ohno R, Emi N, Naoe T. /// Blood. 103:1901-1908,2004
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. /// Hakumei Oh, Fausto R. Loberiza, Jr, Mei-jie Zhang, Olle Ringden, Hideki Akiyama, Takayoshi Asai, Shuichi Miyawaki, Shinichiro Okamoto, Mary M. Horowitz, Joseph H. Antin, Asad Bashey, Jennifer M. Bird, Matthew H. Carabasi, Joseph W. Fay, Robert Peter Gale, Roger H. Giller, John M. Goldman, Gregory A. Hale, Richard E. Harris, Jean Henslee-Downey, Hans-Jochem Kolb, Mark R. Litzow, Philip L. McCarthy, Steven M. Neudorf, Derek S. Serna, Gerard Socie, Pierre Tiberghien, and A. John Barrett. /// Blood 105(4):1408-1416,2005
A randomized study with or without maintenance/intensification chemotherapy in newly diagnosed patients with acute promyelocytic leukemia: the JALSG APL97 study. /// Naoe T, Asou N, Ohno R for the Japan Adult Leukemia Study Group (JALSG). /// Haematologica reports 1: 70-71,2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. /// Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T. /// Blood 106: 2854-2861,2005
A Randomized, Postremission Comparison of Four Courses of Standard-Dose Consolidation Therapy without Maintenance Therapy versus Three Courses of Standard-Dose Consolidation with Maintenance Therapy in Adults with Acute Myeloid Leukemia: The Japan Adult Leukemia Study Group AML97 Study. /// Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R,and for the Japan Adult Leukemia Study Group. /// Cancer 104. 2726-2734,2005
A randomized study with or without maintenance/intensification chemotherapy in newly diagnosed patients with acute promyelocytic leukemia: the JALSG APL97 study. /// Naoe T, Asou N, Ohno R for the Japan Adult Leukemia Study Group (JALSG). /// Haematologica reports 1: 70-71,2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. /// Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T. /// Blood 106: 2854-2861,2005
A Randomized, Postremission Comparison of Four Courses of Standard-Dose Consolidation Therapy without Maintenance Therapy versus Three Courses of Standard-Dose Consolidation with Maintenance Therapy in Adults with Acute Myeloid Leukemia: The Japan Adult Leukemia Study Group AML97 Study. /// Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R,and for the Japan Adult Leukemia Study Group. /// Cancer 104. 2726-2734,2005
High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia: A Phase 2 Study by the Japan Adult Leukemia Study Group. /// Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F,Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y,Ohtake S, Jinnai I, Matsuo K, Naoe T, and Ohno R. /// J Clin Oncoｌ.24:460-466,2006
Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. /// Yanada M, Naoe T. /// Leuk Lymphoma.47:1747-1753,2006
Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. /// Yanada M, Naoe T. /// Leuk Lymphoma.47:1747-1753,2006
Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates. /// Yanada M, Jinnai I, Takeuchi J, Ueda T, Miyawaki S, Tsuzuki M, Hatta Y, Usui N, Wada H, Morii T, Matsuda M, Kiyoi H, Okada M, Honda S, Miyazaki Y, Ohno R, Naoe T. /// Leuk Res 2007; 31(7):907-914.
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. /// Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T. /// Eur J Haematol. 2007 Mar;78(3):213-219.
Prediction of risk of disease recurrence by genome-wide cDNA microarryay analysis in patioents with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined cnemotherapy. /// Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. /// Int J Oncol. 2007; 31:313-322.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy:The Japan Adult Leukemia Study Group(JALSG) APL97 study. /// Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F, Takeshita A, Kimura Y, Iwanaga M, Naoe T, and Ohno R, for the Japan Adult Leukemia Study Group. /// Blood 2007;110:59-66.
Phase I Traial of FLAGM with High Doses of Cytosine Arabinoside for Relapsed, Refractory Acute Myeloid Leukemia: Study of the Japan Adult Leukemia Study Group(JALSG). /// Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Doki N, Ohno R. /// In J Hematol.2007; 86: 343-347.
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. /// Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T. /// Eur J Haematol. 2007 Mar;78(3):213-219.
Prediction of risk of disease recurrence by genome-wide cDNA microarryay analysis in patioents with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined cnemotherapy. /// Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. /// Int J Oncol. 2007; 31:313-322.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy:The Japan Adult Leukemia Study Group(JALSG) APL97 study. /// Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F, Takeshita A, Kimura Y, Iwanaga M, Naoe T, and Ohno R, for the Japan Adult Leukemia Study Group. /// Blood 2007;110:59-66.
Phase I Traial of FLAGM with High Doses of Cytosine Arabinoside for Relapsed, Refractory Acute Myeloid Leukemia: Study of the Japan Adult Leukemia Study Group(JALSG). /// Miyawaki S, Kawai Y, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Doki N, Ohno R. /// In J Hematol.2007; 86: 343-347.
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. /// M Yanada, J Takeuchi, I Sugiura, H Akiyama, N Usui, F Yagasaki, K Nishii, Y Ueda,M Takeuchi, S Miyawaki, A Maruta, H Narimatsu, Y Miyazaki, S Ohtake, I Jinnai, K Matsuo, T Naoe, R Ohno, for the Japan Adult Leukemia Study Group. /// Haematologica 2008; 93:287-290.
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. /// Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M, Ohtake S, Sakamaki H, Miyawaki S, Naoe T, Ohno R, Tomonaga M. /// Int J Hematol 2008; 87: 144-151.
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. /// Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R for the Japan Adult Leukemia Study Group. /// Brit J Haematol.2008;143:503-510.
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. /// Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M, Ohtake S, Sakamaki H, Miyawaki S, Naoe T, Ohno R, Tomonaga M. /// Int J Hematol 2008; 87: 144-151.
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. /// Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R for the Japan Adult Leukemia Study Group. /// Brit J Haematol.2008;143:503-510.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. /// Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T,Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F. /// Blood. 2009 ;113(9):1875-1891.
Management of infection in patients with acute leukemia during chmotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. /// Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T. /// In J Hematol.2009 ;90:191-198.
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. /// Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, DObahsi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R. /// Int J Hematol. 2009; 89: 460-469.
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. /// Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R. /// Int J Hematol. 2009; 89:332-341.
Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. /// Yanada M, Ohno R, Naoe T. /// Int J Hematol. 2009; 89:3-13.
Management of infection in patients with acute leukemia during chmotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. /// Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T. /// In J Hematol.2009 ;90:191-198.
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. /// Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, DObahsi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R. /// Int J Hematol. 2009; 89: 460-469.
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. /// Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R. /// Int J Hematol. 2009; 89:332-341.
Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. /// Yanada M, Ohno R, Naoe T. /// Int J Hematol. 2009; 89:3-13.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. /// Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD. /// Blood. 2010 21;115(3):453-474.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubisin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. /// Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;91:276-283.
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. /// Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;91:97-103.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. /// Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. /// Int J Hematol. 2010 ;91:284-292.
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. /// Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;92:490-502.
Prognostic petential of detection of WT1 mRNA level in peripheral bolld in adult acute myeloid leukemia. /// S Miyawaki, N Hatsumi, T Tamaki, T Naoe, K Ozawa, K Kitamura, T Karasuno, K Mitani, Y Kodera, T Yamagami, D Koga. /// Leukemia & Lymphoma 2010;51:1855-1861.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubisin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. /// Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;91:276-283.
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. /// Morita Y, Kanamaru A, Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K, Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;91:97-103.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. /// Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. /// Int J Hematol. 2010 ;91:284-292.
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. /// Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R. /// Int J Hematol. 2010 ;92:490-502.
Prognostic petential of detection of WT1 mRNA level in peripheral bolld in adult acute myeloid leukemia. /// S Miyawaki, N Hatsumi, T Tamaki, T Naoe, K Ozawa, K Kitamura, T Karasuno, K Mitani, Y Kodera, T Yamagami, D Koga. /// Leukemia & Lymphoma 2010;51:1855-1861.
